Fig 1: Anti-tumor activity of VZnO in orthotopic CRC model. A Experimental timeline of the orthotopic CRC model. B Bioluminescence imaging of orthotopic colon cancer mouse injected with different treatments on day 14. C, D Photograph and volume of the tumors with different treatments on day 14. E Representative H&E stained of liver and tumor tissue on day 14. F Body weights of orthotopic colon cancer model. G The continuously H2S production in mouse model. H Representative GPX4, COX2, NOX1 and TFR1 protein expression by Western Blot in tumor on day 14. Membranes were re-probed for GAPDH expression to show that similar amounts of protein were loaded in each lane. I) H2S content measured on day 14. J The volume of the tumors in the orthotopic breast model on day 14. (*P < 0.05), (n.s.: No significant difference, P value > 0.05)
Fig 2: The H2S scavenging and tumor ferroptosis induced by VZnO in CRC. A The GSH detected by total glutathione assay kit in HCT116 and CT26 after VZnO and ID treatments. B Cell viability by MTT assay in HCT116 and CT26 after VZnO, ID, GSH and Fer-1 treated. C Intracellular ROS levels measured by DCFH-DA assay kit in HCT116 and CT26 with or without VZnO and ID treated. D Colocalization of oxidized lipid and nucleus co-stained by BODIPY C11(green) and DAPI (blue) in HCT116 and CT26 cells. E Representative picture of the ultrastructure of mitochondria in HCT116 and CT26 after VZnO and ID treated. F Average number of mesenchymal cristae per mitochondrion in VZnO-treated cells (statistics of 20 mitochondria) G Representative GPX4, COX2, NOX1 and TFR1 protein expression by Western Blot in HCT116 and CT26 with or without VZnO and ID treated. Membranes were re-probed for GAPDH expression to show that similar amounts of protein were loaded in each lane. (*P < 0.05), (n.s.: No significant difference, P value > 0.05)
Supplier Page from MilliporeSigma for Anti-NOX1 antibody produced in goat